Clinical Data CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment PharmaTimesStudy expands development of the antibody into hepatocellular carcinomaClinical DataOncologyRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) PharmaTimes Study expands development of the antibody into hepatocellular carcinoma Clinical DataOncologyRead full story Post navigation Previous: In the face of tariffs, FDA-approved drug manufacturing deals are shifting to EuropeNext: FDA Seeks Expanded Authority To Regulate Postapproval Manufacturing Changes Related Stories Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival pharminent May 12, 2026 Clinical Data Novo says high-dose Wegovy can cause 28% weight loss pharminent May 12, 2026 Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD pharminent May 11, 2026
